Search Results
Oct 25, 2025, 09:17 ET MENU - ORDER AI Launches October 28, Advancing Healthy Dining Through Artificial Intelligence -- and Preparing for the Next Wave of AGI
Boston-based health-tech startup uses AI to instantly identify healthier restaurant and delivery meals — from High-protein and GLP-1 friendly to low-carb and low Weight Watchers (WW) points — and is developing AGI-driven personalization for the future of intelligent nutrition.
More news about: MENU - ORDER AI
Oct 24, 2025, 09:02 ET Ortho Molecular Products Partners with Calocurb® to Launch Calocurb® CLINICAL, an Exclusive, Clinically Proven Appetite Management Solution Only Available Under the Guidance of Licensed Practitioners
system delivers Amarasate® to the small intestine, where it activates bitter taste receptors (TAS2Rs) on enteroendocrine cells to trigger GLP-1, CCK and PYY, three key satiety and gastric-regulating hormones. "In every product and partnership, we start with one question:
More news about: Calocurb
Oct 24, 2025, 08:00 ET ChemDiv Extends Discovery and Early Development Partnership with Mondego Bio on Best-in-Class PTPN2 Immuno-Oncology Program
discovery biology for backup series, CMC process research and large-scale manufacturing of the lead candidate for non-GLP and GLP animal studies, Computational and wet-lab pharmacology to accelerate clinical readiness.
More news about: ChemDiv
Oct 24, 2025, 06:02 ET 13 Press Releases You Need to See This Week
risk, including those who have not had a prior CV event "As the only FDA-approved GLP-1 therapy in a pill, now recognized for its proven cardiovascular benefits, a new benchmark has been set for future oral innovations," said Dave Moore,
More news about: PR Newswire
Oct 23, 2025, 08:04 ET From Quick Fix to Real Change: L-Nutra Launches the Prolon® Guided Health Program for Weight and Metabolic Wellness
While GLP-1 medications have brought attention to the weight-loss epidemic, they often fail to address the root causes of metabolic disease: insulin resistance,
More news about: L-Nutra Inc.
Oct 23, 2025, 08:00 ET Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity
preservation Combination therapy with a low-dose GLP-1 resulted in synergistic weight loss and lean mass preservation that was maintained off-GLP-1 treatment A Phase 1 open-label study in Australia
More news about: Vial
Oct 23, 2025, 06:00 ET West Reports Third-Quarter 2025 Results
and Contract Manufacturing segments. We achieved double-digit growth in our HVP Components business, driven by our continued execution in GLP-1 products, increased HVP conversion, including Annex 1, and an overall improving demand environment. As a result of the solid performance in the
More news about: West Pharmaceutical Services, Inc.
Oct 22, 2025, 16:05 ET Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
role in developing therapeutics for use in combination with GLP-1 or dual GLP-1/GIP agonists. Amylin agonists could represent attractive treatment options for patients who are not candidates for GLP-1 therapeutics due to tolerability or other reasons.Viking
More news about: Viking Therapeutics, Inc.
Oct 22, 2025, 12:29 ET Surgeons: Obesity Isn't About Willpower -- It's a Treatable Medical Condition
emphasized several factors: GLP-1s require long-term commitment: Most patients with obesity must continue taking GLP-1s for the long term to maintain weight loss, which can be challenging or impractical. Research shows that
More news about: American College of Surgeons
Oct 22, 2025, 10:00 ET CARBONE FINE FOOD LAUNCHES CHEF-CURATED ITALIAN SIMMER SAUCES FOR QUICK, RESTAURANT-QUALITY ITALIAN MEALS AT HOME
awareness and usage of GLP-1 drugs among Gen Z and millennials, with fully 37% of Gen Z seeking to integrate GLP-1 into their health regimen. (eMarketer) Major market research analysts (Mintel, Circana) project US CAGR as high as 18% for GLP-1 products through 2030, and
More news about: Carbone Fine Food
Oct 21, 2025, 16:01 ET Can Ozempic Slow Aging? New Study Raises Hope
years, slowed the pace of aging by nearly 9%, and demonstrated organ-specific rejuvenation. These findings mark the first time a GLP-1 receptor agonist has shown age-reversal effects at the molecular level in humans.
More news about: TruDiagnostic
Oct 21, 2025, 10:36 ET Health-E Commerce® Expands Telehealth Weight Loss Options with MEDVi and Remedy Meds
Shed : New users receive $100 off the first month of any GLP-1 program. Includes unlimited access to licensed providers, one-on-one success managers, and personalized treatment plans.
More news about: Health-E Commerce
Oct 21, 2025, 10:30 ET GLP-1 Agonists Market worth $170.75 billion in 2033 with 13.0% CAGR | MarketsandMarkets™
By indication, the GLP-1 Agonists market is segmented into diabetes, obesity and other indications. In 2024, the diabetes segment dominated the market. GLP-1 agonists are becoming a key drug class in diabetes care because of their
More news about: MarketsandMarkets
Oct 21, 2025, 09:20 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
point-in-time treatment, expanding the company's Rejuva Smart GLP-1 platform from durable treatment of type 2 diabetes to obesity. "These RJVA-002 data further support our Smart GLP-1 gene therapy platform approach and suggest that dual gut hormone expression
More news about: Equity Insider
Oct 21, 2025, 08:39 ET LO SECCO PROSECCO Toasts New England Expansion with Ruby Wines Partnership: Bringing Zero-Sugar Sparkle to Wellness Enthusiasts Across the Region
the timeless elegance of Prosecco with modern wellness credentials. LO SECCO is the ideal toast for Keto, Paleo, Mediterranean, Low Carb and GLP-1 communities and beyond. Through Ruby Wines' storied network—recently bolstered by its new Rhode Island expansion—LO SECCO will sparkle on shelves
More news about: LO SECCO PROSECCO
Oct 21, 2025, 08:23 ET Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances.
More news about: Hoth Therapeutics, Inc.
Oct 21, 2025, 08:03 ET What Will Define the Future of Pharma? Five Trends on Solvias' Radar Ahead of CPHI Frankfurt 2025
The Emergence of Oral GLP-1 Small Molecules "At this year's CPHI, all eyes will be on the next wave of therapies in obesity and diabetes. The emergence of small-molecule oral GLP-1s could reshape the market by 2026, with Eli Lilly's
More news about: Solvias
Oct 21, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Gene Tools Announce Collaboration to Expand Access to PMO Therapeutics
critical gap in the development pipeline by enabling purified PMO production at early research stages and seamlessly bridging to Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) manufacturing.
More news about: Ajinomoto Bio-Pharma Services
Oct 21, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Gene Tools Announce Collaboration to Expand Access to PMO Therapeutics
critical gap in the development pipeline by enabling purified PMO production at early research stages and seamlessly bridging to Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) manufacturing.
More news about: Ajinomoto Bio-Pharma Services
Oct 21, 2025, 07:05 ET Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
and placebo. About GLP-1 and Dual GLP-1/GIP Agonists Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body
More news about: Viking Therapeutics, Inc.
Oct 21, 2025, 02:00 ET Haut.AI Launches Ground Breaking GenAI Powered Skin Aging Simulation
partners with top health plans and employers to offer a suite of solutions, including Noom Med, Noom Weight with SmartRx, Noom Weight, Noom weight with GLP-1Rx, Noom Diabetes, and Noom Diabetes Prevention Program, to millions. Noom has received multiple National Institute of Health grants and was the first
More news about: Haut.AI
Oct 20, 2025, 12:30 ET Highmark and Noom collaborate to improve member health through behavior change and personalized support
confidence. Additionally, Noom's GLP-1 Companion is available to members across all journeys who self-report they are taking a GLP-1 medication. This feature offers customized content such as protein intake guidance, strategies
More news about: Highmark Health
Oct 20, 2025, 10:34 ET MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025
(OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR),
More news about: MetaVia Inc.
Oct 20, 2025, 10:30 ET Compounding Pharmacy Market worth $19.41 billion by 2030 with 5.7% CAGR | MarketsandMarkets™
period. The market growth can be credited to persistent drug shortages in North America and Europe and the continued demand-supply gap for GLP-1 drugs.
More news about: MarketsandMarkets
Oct 20, 2025, 07:00 ET Andel Raises $4.5M for Its Employer-Supported Medication Marketplace
Andel enables employers to offer GLP-1 weight-loss medications as a benefit — at a fraction of the cost of insurance. LAS VEGAS,
More news about: Andel Co-op, Inc.